DWTX Stock Overview
A development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Dogwood Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.16 |
52 Week High | US$26.00 |
52 Week Low | US$2.50 |
Beta | 1.58 |
11 Month Change | -2.12% |
3 Month Change | -19.22% |
1 Year Change | -67.71% |
33 Year Change | -97.15% |
5 Year Change | n/a |
Change since IPO | -99.00% |
Recent News & Updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17Shareholder Returns
DWTX | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | 0.5% | 0.5% |
1Y | -67.7% | 24.7% | 36.8% |
Return vs Industry: DWTX underperformed the US Biotechs industry which returned 27% over the past year.
Return vs Market: DWTX underperformed the US Market which returned 38.6% over the past year.
Price Volatility
DWTX volatility | |
---|---|
DWTX Average Weekly Movement | 19.7% |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DWTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DWTX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 4 | Greg Duncan | www.dwtx.com |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
Dogwood Therapeutics, Inc. Fundamentals Summary
DWTX fundamental statistics | |
---|---|
Market cap | US$5.94m |
Earnings (TTM) | -US$4.68m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs DWTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DWTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$4.68m |
Earnings | -US$4.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.51 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DWTX perform over the long term?
See historical performance and comparison